CYCLOPHOSPHAMIDE IN IMMUNODEPRESSIVE THER APY OF SEVERE APLASTIC-ANEMIA

Low course doses of cyclophosphamide (1.9+/-0.2 g) were given to posts plenectomy patients with grave aplastic anemia (GAA). A total of 27 pa tients aged 14-42 years were treated, 27 control GAA patients did not receive cyclophosphamide. The cyclophosphamide therapy was controlled by T-lymphocyte functional activity assessed in active rosette formati on test with levamisole in vitro. 19 (70.3%) patients were treated twi ce. The remission was achieved in 22 patients (81.5%), partial respons e was in 1 patient (3.7%), 4 patients died (14.8%). In control subject s the remission was recorded only in 4 subjects, 23 patients died 3 to 12 months after splenectomy. It is evident that low-dose courses of c yclophosphamide are highly effective in case of control over immunolog ical activity of the pathological process.